Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

tary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company's major efforts have been focused on projects targeting Raynaud's phenomenon, nail psoriasis and actinic keratosis. In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectation or forecasts of future events. MediQuest's performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, ability to implement its commercial plans, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements please contact the Company. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-looking statement
www.mqti.com

Contact information
Joseph K. Piper
Managing Director, Point B Capital
jpiper@pointbcap.com
206-577-7223

Media Contact: Siavash Forootan MediQuest Therapeutics, 215-238-8881, sforootan@numodacapital.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... April 27 AstraZeneca LP and AstraZeneca ... resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug ... by the Food and Drug Administration (FDA), the Departments ... Fraud Enforcement Action Team (HEAT) announced today.  Such unapproved ...
... April 27 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... traditional Chinese medicines ("TCM"), today announced,the appointment of Mr. Dianjun ... , and that the Company has established nominating and compensation,committees. , ... ...
Cached Medicine Technology:Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 3Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 4Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 5Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 6Renhuang Appoints New Director and Establishes Nominating and Compensation Committee 2Renhuang Appoints New Director and Establishes Nominating and Compensation Committee 3
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... trials for a new experimental drug to treat ... treated with CPX-351, a combination of the chemotherapeutic ... than patients treated with the standard drug formulation. ... an aggressive blood cancer with very low rates ... Jeffrey Lancet, M.D., senior member of the Department ...
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... Abaxis, Inc.,(Nasdaq: ABAX ), a medical products ... Clint Severson, CEO and,President, will participate in the ... on Tuesday, September 9, 2008 at the Shangri-La ... manufactures and markets portable blood analysis,systems for use ...
... 2 /PRNewswire/ - U.S. Preventive Medicine, Inc.,( http://www.USPreventiveMedicine.com ... appointment of Ron Loeppke, M.D., MPH, as Co-Chairman ... focused on researching,the role of primary, secondary and ... in improving health and,productivity in the workplace, as ...
... of Mobility Allows Local Man with Cerebral Palsy to Enjoy ... "It,s a boy!" were,the happy words marking the arrival ... were thrilled and excited at the birth of,their first child, ... cerebral palsy. Things just became a lot easier for,them, thanks ...
... than 60 high-level policymakers, leaders and health experts have adopted ... in developing countries. , The plan, contained in the World ... 2020 and outlines priority steps that need to be taken ... at the close of the World Cancer Congress in Geneva ...
... of developing cardiovascular disease (CVD) over the next 10 years have ... September issue of IJCP, the International Journal of Clinical Practice. ... risk is greatest when it comes to middle-aged men, says the ... out by Oxford University and funded by Unilever. , "The ...
... multi-institutional study to date examining the impact of positron ... with suspected recurrent colorectal cancer, researchers found that treatment ... according to an article in the September issue of ... study was conducted at four sites throughout Australia and ...
Cached Medicine News:Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 2Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 3Health News:The SCOOTER Store Donates Power Wheelchair, Giving New Parents Chance to Be an Active Family 2Health News:World Cancer Declaration sets ambitious targets for 2020 2Health News:Millions face undiagnosed heart risk say researchers after mass screening 2Health News:Millions face undiagnosed heart risk say researchers after mass screening 3Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2
... Diagnostics iQ®200 Automated Urine Microscopy Analyzer ... Recognition (APR®) software to classify urine ... report results. The iQ200 eliminates most ... interpret particle images by automating specimen ...
... The ISOPLATER® is an automatic ... load, streak and stack up to ... hour. Automated streaking results in substantial ... productivity, improves isolation rates, standardizes streaking ...
... a brand-new high technology state-of-the-art system offering ... and ease-of-use for every user. The flexible ... basic investigations as well as research purposes. ... This allows you to obtain the functionality ...
... Delphis™ is ideal for any clinical ... to performing a UDS procedure. Customize ... the options of a Pocket PC, ... Delphis with Bluetooth™ wireless technology allows ...
Medicine Products: